KURA ONCOLOGY INC

Insider buy: Kura Oncology CEO Troy Edward purchases 100k shares after Q2 earnings beat, signaling confidence amid potential upside and dilution risk.

Insider sale of 10,000 Kura Oncology shares at $11.00 shows routine, plan‑based trading; investors should focus on clinical milestones, not individual trades.

Insider sales by Kura Oncology’s execs, including a May 18 sale, reveal a balanced buying‑selling strategy rather than panic, highlighting the need to focus on clinical milestones for future value.